Focused On-demand Library for Eukaryotic peptide chain release factor GTP-binding subunit ERF3A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

G1 to S phase transition protein 1 homolog

Alternative UPACC:

P15170; J3KQG6; Q96GF2


Eukaryotic peptide chain release factor GTP-binding subunit ERF3A, also known as GSPT1 or G1 to S phase transition protein 1 homolog, plays a crucial role in translation termination. It forms part of the eRF1-eRF3-GTP ternary complex, which mediates translation termination at stop codons UAA, UAG, and UGA. This protein is essential for delivering ETF1/ERF1 to stop codons, facilitating GTP hydrolysis, and inducing conformational changes for translation termination. Additionally, ERF3A is a component of the SURF complex, involved in nonsense-mediated decay (NMD) and is required for SHFL-mediated translation termination, which inhibits programmed ribosomal frameshifting.

Therapeutic significance:

Understanding the role of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.